The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.
 
B.J. Rimel
Honoraria - Genentech
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Deep 6 AI; Genentech/Roche; GlaxoSmithKline; Merck; Tesaro
 
David Bender
No Relationships to Disclose
 
Danielle Enserro
No Relationships to Disclose
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; Bayer; BioAscent; Caris Life Sciences; Clovis Oncology; Curio Science; Eisai; EQRX; Genentech; Gerson Lehrman Group; GlaxoSmithKline; Immunogen; Lilly; Medscape; Merck; Mereo BioPharma; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; OncLive; Roche; Seagen; Targeted Oncology; Vaniam Group; Vincerx Pharma; Zentalis
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Mereo BioPharma (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Roche/Genentech (Inst); Zentalis (Inst)
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Immunogen; Mersana
Research Funding - Aravive (Inst); Arch Oncology (Inst); ArQule (Inst); AstraZeneca (Inst); Celsion (Inst); Clovis Oncology (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Plexxikon (Inst); Roche (Inst); Shattuck Labs (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Laura L. Holman
No Relationships to Disclose
 
Nitya Alluri
No Relationships to Disclose
 
Ashley Stuckey
Consulting or Advisory Role - UpToDate
 
Ruchi Garg
Employment - Cancer Treament Centers of America
Leadership - Cancer Treament Centers of America
Speakers' Bureau - AstraZeneca; Merck
 
Sarah Gill
No Relationships to Disclose
 
Edward Tanner
Consulting or Advisory Role - Johnson & Johnson/Janssen
Speakers' Bureau - AstraZeneca; Eisai; ImmunoGen (I); Merck
 
Charles A. Leath
Consulting or Advisory Role - GlaxoSmithKline; GOG Foundation; Immunogen; Merck; Natera; Seagen
Research Funding - Abbvie (Inst); Agenus (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Celsion (Inst); Corcept Therapeutics (Inst); Immunogen (Inst); Merck (Inst); Rubius Therapeutics (Inst); Seagen (Inst); Tesaro (Inst)
 
Floor Jenniskens Backes
Consulting or Advisory Role - Abbott Diagnostics (I); Agenus; Agenus; AstraZeneca; Clovis Oncology; CMR Institute; Eisai; GlaxoSmithKline; Immunogen; Merck; Myriad Genetics; natera (Inst)
Research Funding - Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate (for writing a chapter)
 
Aimee Fleury
No Relationships to Disclose
 
Helen Mackay
Honoraria - AstraZeneca; GlaxoSmithKline
Consulting or Advisory Role - Eisai; GlaxoSmithKline; Merck